HopeStage
Back to all studies
CompletedNCT02526030

Three-Year Comparison of Antipsychotics for First-Episode Psychosis

About this titleRead the official source — NCT02526030
Medication studyAges 18–65SpainSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
SantanderSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 2008
Recruitment status
Completed
Enrollment listed in the registry
203
Sponsor
Fundación Marques de Valdecilla
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Spain
Age range
From 18 Years to 65 Years
Official registry ID
NCT02526030
Official title
Show the full official title

Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Santander

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Fundación Marques de Valdecilla.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole, Quetiapine and Ziprasidone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies